ConductScience.org, home

Paper41868151

Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study.

Zhang Y and 6 others. Front Cell Infect Microbiol, 2026. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study. Papers, record 41868151. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/41868151

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Based a machine learning approach to investigate the factors influencing nirmatrelvir/ritonavir exposure in human plasma: a multicenter, observational study.
PubMed
Journal
Front Cell Infect Microbiol
PubMed
Year
2026
PubMed
Publication types
Journal Article, Multicenter Study, Observational Study
PubMed
Citations, by iCite
1
iCite
Revised in PubMed
2026-08-13
PubMed

Authors7

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zhang YYue
2Yang XXiner
3Sun LLiang
4Zhang RRuncong
5Fan WWeibin
6Lin NNengming
7Lin BBin

Source PubMed

Download CSV of authors

Topics16

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
RitonavirMajor topic
Machine LearningMajor topic
Antiviral AgentsMajor topic
COVID-19 Drug TreatmentMajor topic
Humans
Drug Monitoring
Female
Retrospective Studies
Male
Middle Aged
SARS-CoV-2
COVID-19
Predictive Learning Models
Boosting Machine Learning Algorithms
Aged
Adult

Source PubMed

Download CSV of topics

References34

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
137562225Overview of therapeutic drug monitoring and clinical practice.Talanta2024https://conductscience.org/library/papers/37562225PubMed
232934000Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-analysis.BMJ Evid Based Med2021https://conductscience.org/library/papers/32934000PubMed
336577095VV116 versus Nirmatrelvir-Ritonavir for Oral Treatment of Covid-19.N Engl J Med2023https://conductscience.org/library/papers/36577095PubMed
435623373The future of Paxlovid for COVID-19.Lancet Respir Med2022https://conductscience.org/library/papers/35623373PubMed
535617192Correction: Prognostic factors for severity and mortality in patients infected with COVID-19: A systematic review.PLoS One2022https://conductscience.org/library/papers/35617192PubMed
635153195Disposition of Nirmatrelvir, an Orally Bioavailable Inhibitor of SARS-CoV-2 3C-Like Protease, across Animals and Humans.Drug Metab Dispos2022https://conductscience.org/library/papers/35153195PubMed
737565522Real-world Effectiveness of Molnupiravir and Nirmatrelvir/Ritonavir as Treatments for COVID-19 in Patients at High Risk.J Infect Dis2023https://conductscience.org/library/papers/37565522PubMed
836576379Efficacy and safety of nirmatrelvir/ritonavir (Paxlovid) for COVID-19: A rapid review and meta-analysis.J Med Virol2023https://conductscience.org/library/papers/36576379PubMed
928255613Intensive care medicine research agenda on invasive fungal infection in critically ill patients.Intensive Care Med2017https://conductscience.org/library/papers/28255613PubMed
1034818379Association between voriconazole exposure and Sequential Organ Failure Assessment (SOFA) score in critically ill patients.PLoS One2021https://conductscience.org/library/papers/34818379PubMed
1137904658Effectiveness and Adverse Events of Nirmatrelvir/Ritonavir Versus Molnupiravir for COVID-19 in Outpatient Setting: Multicenter Prospective Observational Study.J Korean Med Sci2023https://conductscience.org/library/papers/37904658PubMed
1231640781Random forest-based modelling to detect biomarkers for prostate cancer progression.Clin Epigenetics2019https://conductscience.org/library/papers/31640781PubMed
1336274268Simultaneous quantification of nirmatrelvir and ritonavir by LC-MS/MS in patients treated for COVID-19.J Chromatogr B Analyt Technol Biomed Life Sci2022https://conductscience.org/library/papers/36274268PubMed
1427165788Utility of voriconazole therapeutic drug monitoring: a meta-analysis.J Antimicrob Chemother2016https://conductscience.org/library/papers/27165788PubMed
1537018987Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?Biomed Pharmacother2023https://conductscience.org/library/papers/37018987PubMed
1634914868Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients.N Engl J Med2022https://conductscience.org/library/papers/34914868PubMed
1735118917Efficacy and safety of three new oral antiviral treatment (molnupiravir, fluvoxamine and Paxlovid) for COVID-19:a meta-analysis.Ann Med2022https://conductscience.org/library/papers/35118917PubMed
1836031408Impact of the Use of Oral Antiviral Agents on the Risk of Hospitalization in Community Coronavirus Disease 2019 Patients (COVID-19).Clin Infect Dis2023https://conductscience.org/library/papers/36031408PubMed
1935026171Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.Lancet Gastroenterol Hepatol2022https://conductscience.org/library/papers/35026171PubMed
2034048671Lopinavir/Ritonavir for COVID-19: a Systematic Review and Meta-Analysis.J Pharm Pharm Sci2021https://conductscience.org/library/papers/34048671PubMed

See all 34 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
42724114Therapeutic drug monitoring of zonisamide in children with epilepsy: development and validation of a precise binary prediction model.Front Pharmacol2026https://conductscience.org/library/papers/42724114

Source PubMed

Download CSV of cited by

Genes3

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
CMPK151727PubTator's text mininghttps://conductscience.org/library/genes/51727NCBI Gene
GPT2875PubTator's text mininghttps://conductscience.org/library/genes/2875NCBI Gene
SLC17A526503PubTator's text mininghttps://conductscience.org/library/genes/26503NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/41868151

GET https://conductscience.org/api/papers/v1/41868151/references?page=2